JP2024523438A5 - - Google Patents

Info

Publication number
JP2024523438A5
JP2024523438A5 JP2023578700A JP2023578700A JP2024523438A5 JP 2024523438 A5 JP2024523438 A5 JP 2024523438A5 JP 2023578700 A JP2023578700 A JP 2023578700A JP 2023578700 A JP2023578700 A JP 2023578700A JP 2024523438 A5 JP2024523438 A5 JP 2024523438A5
Authority
JP
Japan
Prior art keywords
mol
body weight
total
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/066764 external-priority patent/WO2022268740A1/en
Publication of JP2024523438A publication Critical patent/JP2024523438A/ja
Publication of JP2024523438A5 publication Critical patent/JP2024523438A5/ja
Pending legal-status Critical Current

Links

JP2023578700A 2021-06-21 2022-06-20 Cd137結合物質とpd-l1結合物質の組合せ投薬レジメン Pending JP2024523438A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163212781P 2021-06-21 2021-06-21
US63/212,781 2021-06-21
US202163257879P 2021-10-20 2021-10-20
US63/257,879 2021-10-20
PCT/EP2022/066764 WO2022268740A1 (en) 2021-06-21 2022-06-20 Combination dosage regime of cd137 and pd-l1 binding agents

Publications (2)

Publication Number Publication Date
JP2024523438A JP2024523438A (ja) 2024-06-28
JP2024523438A5 true JP2024523438A5 (cg-RX-API-DMAC10.html) 2025-06-27

Family

ID=82358492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578700A Pending JP2024523438A (ja) 2021-06-21 2022-06-20 Cd137結合物質とpd-l1結合物質の組合せ投薬レジメン

Country Status (8)

Country Link
US (1) US20240262924A1 (cg-RX-API-DMAC10.html)
EP (1) EP4359435A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024523438A (cg-RX-API-DMAC10.html)
BR (1) BR112023027006A2 (cg-RX-API-DMAC10.html)
CA (1) CA3223375A1 (cg-RX-API-DMAC10.html)
IL (1) IL309319A (cg-RX-API-DMAC10.html)
TW (1) TW202315891A (cg-RX-API-DMAC10.html)
WO (1) WO2022268740A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
IN2014CN03887A (cg-RX-API-DMAC10.html) 2011-10-27 2015-10-16 Genmab As
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
CN106459165B (zh) 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
SMT201900702T1 (it) 2015-01-08 2020-01-14 Genmab As Agenti agonistici leganti il recettore del tnf
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
US20230057602A1 (en) * 2019-11-05 2023-02-23 Bristol-Myers Squibb Company Methods of treatment with antibodies against bcma and cd3

Similar Documents

Publication Publication Date Title
JP2022050522A (ja) 癌の治療のための併用療法
US20240075133A1 (en) Methods and compositions for reduction of immunogenicity
EP3896089A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
JP2024525758A5 (cg-RX-API-DMAC10.html)
CN118201613A (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
JP2023551980A5 (cg-RX-API-DMAC10.html)
WO2020225552A1 (en) Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
CN120344271A (zh) 抗her2抗体药物偶联物治疗乳腺癌
CN115087461A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
JP2024536383A5 (cg-RX-API-DMAC10.html)
WO2025082449A1 (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
TW202545570A (zh) 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用
KR20190107719A (ko) 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정
JP2024538755A5 (cg-RX-API-DMAC10.html)
TW202114663A (zh) EZH2抑制劑與含有TGF-β受體的融合蛋白聯合在製備治療腫瘤的藥物中的用途
JP2022548881A5 (cg-RX-API-DMAC10.html)
TW202143969A (zh) 抗pd-1抗體和多受體酪胺酸激酶抑制劑的藥物組合及其使用方法
US20260130922A1 (en) Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
US20250011453A1 (en) Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
US20220259316A1 (en) Multiple-Variable Dosage Regimen for the Treatment of Cancers with High Expression of EGFR
WO2026021442A1 (zh) 抗体药物偶联物在制备治疗肺癌的药物中的用途
WO2026026912A1 (zh) 抗体药物偶联物和抗vegf抗体的联合应用
HK40124723A (en) Combined use of an antibody-drug conjugate and an immune checkpoint inhibitor
TW202446792A (zh) 使用可活化抗ctla4抗體與pembrolizumab組合治療癌症之方法